Novel insights into proteolytic cleavage of influenza virus hemagglutinin

Reviews in Medical Virology

Volumn 20, Issue 5, 2010, Pages 298-310

  Bertram, Stephanie ^a   Glowacka, Ilona ^a   Steffen, Imke ^a   Kühl, Annika ^a   Pöhlmann, Stefan ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FURIN; HEMAGGLUTININ; PROTEINASE; TMPRSS2 ENZYME; TMPRSS4 ENZYME; TRYPSIN LIKE PORTEASE; TRYPTASE; UNCLASSIFIED DRUG;

AVIAN INFLUENZA VIRUS; CHEMICAL STRUCTURE; GOLGI COMPLEX; HUMAN; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; VIRUS ENVELOPE;

HEMAGGLUTININS, VIRAL; HUMANS; ORTHOMYXOVIRIDAE; PEPTIDE HYDROLASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRUS INTERNALIZATION;

EID: 77956639165     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.657     Document Type: Review

References (105)

1. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009; 459: 931-939.
2. Palese P. Influenza: old and new threats. Nat Med 2004; 10: S82-S87.
3. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J Am Med Assoc 2003; 289: 179-186. (Pubitemid 36068705)
4. Belshe RB. The origins of pandemic influenza-lessons from the 1918 virus. N Engl J Med 2005; 353: 2209-2211.
5. Parrish CR, Kawaoka Y. The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses. Annu Rev Microbiol 2005; 59: 553-586. (Pubitemid 41507442)
6. Morens DM, Taubenberger JK. Understanding influenza backward. J Am Med Assoc 2009; 302: 679-680.
7. Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. J Infect Dis 2007; 195: 1018-1028.
8. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-2615.
9. Fraser C, Donnelly CA, Cauchemez S, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324: 1557-1561.
10. http://www.who.int/csr/disease/swineflu/laboratory18-12-2009/en/index. html WHO, update 79, accessed on 21 Dec 2009.
11. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460: 1021-1025.
12. Munster VJ, de Wit E, van den Brand JM, et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325: 481-483.
13. Ellebedy AH, Webby RJ. Influenza vaccines. Vaccine 2009; 27 (Suppl 4): D65-D68.
14. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008; 78: 91-102.
15. von Itzstein M, Thomson R. Anti-influenza drugs: the development of sialidase inhibitors. Handb Exp Pharmacol 2009; 111-154.
16. Basler CF. Influenza viruses: basic biology and potential drug targets. Infect Disord Drug Target 2007; 7: 282-293.
17. Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis 2009; 48: 1254-1256.
18. Steinhauer DA. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999; 258: 1-20.
19. Böttcher E, Matrosovich T, Beyerle M, et al. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol 2006; 80: 9896-9898. (Pubitemid 44435664)
20. Chaipan C, Kobasa D, Bertram S, et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. J Virol 2009; 83: 3200-3211.
21. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69: 531-569.
22. Harrison SC. Viral membrane fusion. Nat Struct Mol Biol 2008; 15: 690-698.
23. Lakadamyali M, Rust MJ, Zhuang X. Endocytosis of influenza viruses. Microb Infect 2004; 6: 929-936.
24. Skehel JJ, Bayley PM, Brown EB, et al. Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci USA 1982; 79: 968-972.
25. Copeland CS, Zimmer KP, Wagner KR, et al. Folding, trimerization, and transport are sequential events in the biogenesis of influenza virus hemagglutinin. Cell 1988; 53: 197-209.
26. Hebert DN, Foellmer B, Helenius A. Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. Cell 1995; 81: 425-433.
27. Daniels RS, Downie JC, Hay AJ, et al. Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell 1985; 40: 431-439.
28. Garten W, Klenk HD. Understanding influenza virus pathogenicity. Trend Microbiol 1999; 7: 99-100.
29. Klenk HD, Garten W. Host cell proteases controlling virus pathogenicity. Trend Microbiol 1994; 2: 39-43. (Pubitemid 24051419)
30. Garten W, Klenk HD. Characterization of the carboxypeptidase involved in the proteolytic cleavage of the influenza haemagglutinin. J Gen Virol 1983; 64: 2127-2137.
31. Chen J, Lee KH, Steinhauer DA, et al. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 1998; 95: 409-417.
32. Reed ML, Yen HL, DuBois RM, et al. Amino acid residues in the fusion peptide pocket regulate the pH of activation of the H5N1 influenza virus hemagglutinin protein. J Virol 2009; 83: 3568-3580.
33. Bosch FX, Garten W, Klenk HD, et al. Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses. Virology 1981; 113: 725-735. (Pubitemid 11056361)
34. Perdue ML, Garcia M, Senne D, et al. Virulence-associated sequence duplication at the hemagglutinin cleavage site of avian influenza viruses. Virus Res 1997; 49: 173-186.
35. Webster RG, Rott R. Influenza virus A pathogenicity: the pivotal role of hemagglutinin. Cell 1987; 50: 665-666.
36. Stieneke-Grober A, Vey M, Angliker H, et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 1992; 11: 2407-2414.
37. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3: 753-766.
38. Ohuchi M, Orlich M, Ohuchi R, et al. Mutations at the cleavage site of the hemagglutinin after the pathogenicity of influenza virus A/chick/Penn/83 (H5N2). Virology 1989; 168: 274-280. (Pubitemid 19073305)
39. Ohuchi R, Ohuchi M, Garten W, et al. Human influenza virus hemagglutinin with high sensitivity to proteolytic activation. J Virol 1991; 65: 3530-3537.
40. Kawaoka Y, Naeve CW, Webster RG. Is virulence of H5N2 influenza viruses in chickens associated with loss of carbohydrate from the hemagglutinin? Virology 1984; 139: 303-316.
41. Deshpande KL, Fried VA, Ando M, et al. Glycosylation affects cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence. Proc Natl Acad Sci USA 1987; 84: 36-40.
42. Reid AH, Fanning TG, Hultin JV, et al. Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci USA 1999; 96: 1651-1656.
43. Klenk HD, Rott R, Orlich M, et al. Activation of influenza A viruses by trypsin treatment. Virology 1975; 68: 426-439.
44. Klenk HD, Rott R, Orlich M. Further studies on the activation of influenza virus by proteolytic cleavage of the haemagglutinin. J Gen Virol 1977; 36: 151-161. (Pubitemid 8136965)
45. Lazarowitz SG, Choppin PW. Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 1975; 68: 440-454.
46. Vey M, Orlich M, Adler S, et al. Hemagglutinin activation of pathogenic avian influenza viruses of serotype H7 requires the protease recognition motif R-X-K/R-R. Virology 1992; 188: 408-413.
47. de Curtis I, Simons K. Isolation of exocytic carrier vesicles from BHK cells. Cell 1989; 58: 719-727.
48. Ito T, Goto H, Yamamoto E, et al. Generation of a highly pathogenic avian influenza A virus from an avirulent field isolate by passaging in chickens. J Virol 2001; 75: 4439-4443.
49. Horimoto T, Kawaoka Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J Virol 1994; 68: 3120-3128. (Pubitemid 24129761)
50. Stech O, Veits J, Weber S, et al. Acquisition of a polybasic hemagglutinin cleavage site by a low-pathogenic avian influenza virus is not sufficient for immediate transformation into a highly pathogenic strain. J Virol 2009; 83: 5864-5868.
51. Hallenberger S, Bosch V, Angliker H, et al. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 1992; 360: 358-361.
52. Bolt G, Pedersen LO, Birkeslund HH. Cleavage of the respiratory syncytial virus fusion protein is required for its surface expression: role of furin. Virus Res 2000; 68: 25-33. (Pubitemid 30621408)
53. Ozden S, Lucas-Hourani M, Ceccaldi PE, et al. Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein. J Biol Chem 2008; 283 21899-21908.
54. Klimpel KR, Molloy SS, Thomas G, et al. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci USA 1992; 89: 10277-10281.
55. Molloy SS, Bresnahan PA, Leppla SH, et al. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-XX-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 1992; 267: 16396-16402.
56. Gordon VM, Benz R, Fujii K, et al. Clostridium septicum alpha-toxin is proteolytically activated by furin. Infect Immun 1997; 65: 4130-4134.
57. Remacle AG, Shiryaev SA, Oh ES, et al. Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem 2008; 283: 20897-20906.
58. Shiryaev SA, Remacle AG, Ratnikov BI, et al. Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem 2007; 282: 20847-20853.
59. Kido H, Yokogoshi Y, Sakai K, et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 1992; 267: 13573-13579.
60. Murakami M, Towatari T, Ohuchi M, et al. Miniplasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus. Eur J Biochem 2001; 268: 2847-2855.
61. Towatari T, Ide M, Ohba K, et al. Identification of ectopic anionic trypsin I in rat lungs potentiating pneumotropic virus infectivity and increased enzyme level after virus infection. Eur J Biochem 2002; 269: 2613-2621.
62. Kido H, Okumura Y, Yamada H, et al. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr Pharm Des 2007; 13: 405-414. (Pubitemid 46477761)
63. Tashiro M, Ciborowski P, Reinacher M, et al. Synergistic role of staphylococcal proteases in the induction of influenza virus pathogenicity. Virology 1987; 157: 421-430.
64. Tashiro M, Ciborowski P, Klenk HD, et al. Role of Staphylococcus protease in the development of influenza pneumonia. Nature 1987; 325: 536-537. (Pubitemid 17056736)
65. Kuiken T, Taubenberger JK. Pathology of human influenza revisited. Vaccine 2008; 26 (Suppl 4): D59-D66.
66. Scheiblauer H, Reinacher M, Tashiro M, et al. Interactions between bacteria and influenza A virus in the development of influenza pneumonia. J Infect Dis 1992; 166: 783-791.
67. Zhirnov OP, Ikizler MR, Wright PF. Cleavage of influenza a virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases. J Virol 2002; 76: 8682-8689.
68. Endo Y, Carroll KN, Ikizler MR, et al. Growth of influenza A virus in primary, differentiated epithelial cells derived from adenoids. J Virol 1996; 70: 2055-2058.
69. Wang W, Butler EN, Veguilla V, et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Method 2008; 153: 111-119.
70. Kido H, Okumura Y, Takahashi A, et al. Host envelope glycoprotein processing proteases are indispensable for entry into human cells by seasonal and highly pathogenic avian influenza viruses. J Mol Genet Med 2008; 3: 167-175.
71. Choi SY, Bertram S, Glowacka I, et al. Type II transmembrane serine proteases in cancer and viral infections. Trends Mol Med 2009; 15: 303-312.
72. Scott HS, Kudoh J, Wattenhofer M, et al. Insertion of beta-satellite repeats identifies a transmembrane protease causing both congenital and childhood onset autosomal recessive deafness. Nat Genet 2001; 27: 59-63.
73. List K, Haudenschild CC, Szabo R, et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002; 21: 3765-3779.
74. Szabo R, Bugge TH. Type II transmembrane serine proteases in development and disease. Int J Biochem Cell Biol 2008; 40: 1297-1316.
75. Yasuoka S, Ohnishi T, Kawano S, et al. Purification, characterization, and localization of a novel trypsin-like protease found in the human airway. Am J Respir Cell Mol Biol 1997; 16: 300-308.
76. Hooper JD, Clements JA, Quigley JP, et al. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001; 276: 857-860.
77. Jacquinet E, Rao NV, Rao GV, et al. Cloning, genomic organization, chromosomal assignment and expression of a novel mosaic serine proteinase: epitheliasin. FEBS Lett 2000; 468: 93-100. (Pubitemid 30101689)
78. Böttcher E, Freuer C, Steinmetzer T, et al. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine 2009; 27: 6324-6329.
79. Wallrapp C, Hahnel S, Muller-Pillasch F, et al. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res 2000; 60: 2602-2606.
80. Jacquinet E, Rao NV, Rao GV, et al. Cloning and characterization of the cDNA and gene for human epitheliasin. Eur J Biochem 2001; 268: 2687-2699.
81. Lucas JM, True L, Hawley S, et al. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol 2008; 215: 118-125.
82. Garten W, Matrosovich M, Matrosovich T, et al. Cleavage of influenza virus hemagglutinin by host cell proteases. International Congress Series 2004; 1263: 218-221.
83. Takahashi M, Sano T, Yamaoka K, et al. Localization of human airway trypsin-like protease in the airway: an immunohistochemical study. Histochem Cell Biol 2001; 115: 181-187. (Pubitemid 32247194)
84. Jung H, Lee KP, Park SJ, et al. TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition. Oncogene 2008; 27: 2635-2647.
85. Kim DR, Sharmin S, Inoue M, et al. Cloning and expression of novel mosaic serine proteases with and without a transmembrane domain from human lung. Biochim Biophys Acta 2001; 1518: 204-209.
86. Zhirnov O, Klenk HD. Human influenza A viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells. Virology 2003; 313: 198-212. (Pubitemid 37013604)
87. Chandran K, Sullivan NJ, Felbor U, et al. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005; 308: 1643-1645.
88. Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 2005; 102: 11876-11881.
89. Boycott R, Klenk HD, Ohuchi M. Cell tropism of influenza virus mediated by hemagglutinin activation at the stage of virus entry. Virology 1994; 203: 313-319.
90. Sugiura A, Ueda M. Neurovirulence of influenza virus in mice. I. Neurovirulence of recombinants between virulent and avirulent virus strains. Virology 1980; 101: 440-449.
91. Castrucci MR, Kawaoka Y. Biologic importance of neuraminidase stalk length in influenza A virus. J Virol 1993; 67: 759-764. (Pubitemid 23032053)
92. Lazarowitz SG, Goldberg AR, Choppin PW. Proteolytic cleavage by plasmin of the HA polypeptide of influenza virus: host cell activation of serum plasminogen. Virology 1973; 56: 172-180.
93. Schulman JL, Palese P. Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells. J Virol 1977; 24: 170-176.
94. Li S, Schulman J, Itamura S, et al. Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus. J Virol 1993; 67: 6667-6673.
95. Goto H, Kawaoka Y. A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc Natl Acad Sci USA 1998; 95: 10224-10228. (Pubitemid 28415322)
96. Goto H, Wells K, Takada A, et al. Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus. J Virol 2001; 75: 9297-9301.
97. Taubenberger JK. Influenza virus hemagglutinin cleavage into HA1, HA2: no laughing matter. Proc Natl Acad Sci USA 1998; 95: 9713-9715.
98. Reid AH, Fanning TG, Janczewski TA, et al. Characterization of the 1918 "Spanish" influenza virus neuraminidase gene. Proc Natl Acad Sci USA 2000; 97: 6785-6790.
99. Tumpey TM, Basler CF, Aguilar PV, et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005; 310: 77-80.
100. Lebouder F, Morello E, Rimmelzwaan GF, et al. Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin. J Virol 2008; 82: 6820-6828.
101. Ovcharenko AV, Zhirnov OP. Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice. Antiviral Res 1994; 23: 107-118.
102. Zhirnov OP, Ovcharenko AV, Bukrinskaia AG, et al. Antiviral and therapeutic action of protease inhibitors in viral infections: experimental and clinical observations. Vopr Virusol 1984; 29: 491-497.
103. Kim TS, Heinlein C, Hackman RC, et al. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol 2006; 26: 965-975.
104. Shirogane Y, Takeda M, Iwasaki M, et al. Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2. J Virol 2008; 82: 8942-8946.
105. Kam YW, Okumura Y, Kido H, et al. Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro. PLoS One 2009; 4: e7870.